PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
36.29%
Revenue growth similar to ACB.TO's 38.97%. Walter Schloss would see if both companies share industry tailwinds.
57.21%
Gross profit growth 1.25-1.5x ACB.TO's 50.68%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
-181.24%
Negative EBIT growth while ACB.TO is at 140.22%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-181.24%
Negative operating income growth while ACB.TO is at 61.76%. Joel Greenblatt would press for urgent turnaround measures.
-57.90%
Negative net income growth while ACB.TO stands at 173.92%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-53.60%
Negative EPS growth while ACB.TO is at 171.60%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-60.74%
Negative diluted EPS growth while ACB.TO is at 154.21%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.09%
Share reduction more than 1.5x ACB.TO's 36.40%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.10%
Diluted share reduction more than 1.5x ACB.TO's 5.43%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
210.71%
Positive OCF growth while ACB.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
-9.01%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52.57%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
4994.38%
Positive OCF/share growth while ACB.TO is negative. John Neff might see a comparative advantage in operational cash viability.
1997.53%
3Y OCF/share CAGR above 1.5x ACB.TO's 33.09%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
733.01%
Below 50% of ACB.TO's 20729.45%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
838.92%
5Y net income/share CAGR above 1.5x ACB.TO's 203.26%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
2455.14%
3Y net income/share CAGR above 1.5x ACB.TO's 154.08%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1295.21%
10Y equity/share CAGR above 1.5x ACB.TO's 579.17%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
2660.69%
5Y equity/share CAGR above 1.5x ACB.TO's 1027.79%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
6638.11%
3Y equity/share CAGR above 1.5x ACB.TO's 489.21%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52.39%
Firm’s AR is declining while ACB.TO shows 96.86%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
43.08%
Inventory growth well above ACB.TO's 50.42%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
30.23%
Asset growth above 1.5x ACB.TO's 7.80%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
30.94%
Positive BV/share change while ACB.TO is negative. John Neff sees a clear edge over a competitor losing equity.
-3.01%
We’re deleveraging while ACB.TO stands at 4.74%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-13.16%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
10.77%
SG&A growth well above ACB.TO's 19.34%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.